Vagus Nerve Stimulators (VNS) Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$4000
Buy Report View Sample

Published: May 25, 2023 Report Code: GDME1550EPD-ST

Select Item

VNS Pipeline Market Report Overview

A VNS is a device comprised of an electrical pacemaker that sends electrical stimulation through surgically implanted electrodes to target the vagus nerve. VNSs are utilized to treat neurological disorders like epilepsy and depression.

The VNS pipeline market research report provides comprehensive information about the VNS pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Key Territories ·       The US

·       Europe

·       India

·       Japan

·       The UK
Key Regulatory Paths ·       PMA

·       510(k)

·       CE

·       ICAC

·       TGA

·       UKCA

·       De Novo
Leading Companies ·       Adriakaim Inc

·       Afferent Technologies

·       Aucta Technologies Inc

·       AURIMOD GmbH

·       Boston Scientific Corp

·       Cala Health Inc

·       CerboMed GmbH

·       Cyberonics Inc

·       DuoCure Ltd.

·       ElectroCore Inc

·       Evren Technologies Inc
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

VNS Pipeline Market Segmentation by Territories

Some of the key territories in the VNS market are the US, Europe, India, Japan, and the UK among others. As of May 2023, the US has the highest number of pipeline products.

VNS Pipeline Market Analysis, by Territories, 2023 (%)

VNS Pipeline Market Analysis, by Territories, 2023 (%)

For more territory insights into the VNS pipeline market, download a free report sample

VNS Pipeline Market Segmentation by Regulatory Paths

Some of the regulatory paths in the VNS pipeline market are PMA, 510(k), CE, ICAC, TGA, UKCA, and De Novo among others. As of May 2023, PMA is the most followed pathway for pipeline products.

VNS Pipeline Market Analysis, by Regulatory Paths, 2023 (%)

VNS Pipeline Market Analysis, by Regulatory Paths, 2023 (%)

For more regulatory path insights into the VNS pipeline market, download a free report sample

VNS Pipeline Market – Competitive Landscape

Some of the key companies in the VNS pipeline market are Adriakaim Inc, Afferent Technologies, Aucta Technologies Inc, Boston Scientific Corp, Cala Health Inc, CerboMed GmbH, Cyberonics Inc, DuoCure Ltd., ElectroCore Inc, and Evren Technologies Inc among others.

Adriakaim Inc: Adriakaim Inc, is engaged in planning, research, design, development, manufacturing, and sales of medical and health-related equipment that stimulates the vagus nerve and reduces the myocardial infarction area. The company is headquartered in Japan.

Segments Covered in the Report

VNS Pipeline Market Territories Outlook

  • The US
  • Europe
  • India
  • Japan
  • The UK

VNS Pipeline Market Regulatory Paths Outlook

  • PMA
  • 510(k)
  • CE
  • ICAC
  • TGA
  • UKCA
  • De Novo

Scope

  • Extensive coverage of the VNS under development

  • Reviews details of major pipeline products which include, product description, licensing and collaboration details, and other developmental activities

  • Reviews the major players involved in the development of VNS and list all their pipeline projects

  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

  • The report provides key clinical trial data of ongoing trials specific to pipeline products

  • Recent developments in the segment/industry

Reasons to Buy

The report enables you to:

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies

  • Identify emerging players with potentially strong product portfolios and create effective counter strategies to gain a competitive advantage

  • Identify and understand important and diverse types of VNS under development

  • Develop market-entry and market-expansion strategies

  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

  • In-depth analysis of the product’s current stage of development, territory, and estimated launch date

Adriakaim Inc
Afferent Technologies
Aucta Technologies Inc
AURIMOD GmbH
Boston Scientific Corp
Cala Health Inc
CerboMed GmbH
Cyberonics Inc
DuoCure Ltd.
ElectroCore Inc
Evren Technologies Inc
Flint Rehabilitation
FRD Accel LLC
LivaNova PLC
Medical University of South Carolina
MicroTransponder Inc
Nemechek Technologies LLC
Nexeon MedSystems Inc
Otto Bock HealthCare GmbH
Parasym Ltd
Pulsetto UAB
Pulsus Medical LLC (Inactive)
Purdue University
ReShape Lifesciences Inc
Soterix Medical Inc
SUNY Downstate Medical Center
Synergia Medical SA
Texas Biomedical Device Center
The Feinstein Institute for Medical Research
Trifectas Medical Corp.
University of Alabama
University of Auckland
University of Pittsburgh
University of Wisconsin Madison
VA Pittsburgh Healthcare System

Table of Contents

  • 1 Table of Contents

    • 1.1 List of Tables

    • 1.2 List of Figures

  • 2 Introduction

    • 2.1 Vagus Nerve Stimulators (VNS) Overview

  • 3 Products under Development

    • 3.1 Vagus Nerve Stimulators (VNS) – Pipeline Products by Stage of Development

    • 3.2 Vagus Nerve Stimulators (VNS) – Pipeline Products by Territory

    • 3.3 Vagus Nerve Stimulators (VNS) – Pipeline Products by Regulatory Path

    • 3.4 Vagus Nerve Stimulators (VNS) – Pipeline Products by Estimated Approval Date

    • 3.5 Vagus Nerve Stimulators (VNS) – Ongoing Clinical Trials

  • 4 Vagus Nerve Stimulators (VNS) – Pipeline Products under Development by Companies

    • 4.1 Vagus Nerve Stimulators (VNS) Companies – Pipeline Products by Stage of Development

    • 4.2 Vagus Nerve Stimulators (VNS) – Pipeline Products by Stage of Development

  • 5 Vagus Nerve Stimulators (VNS) Companies and Product Overview

    • 5.1 Adriakaim Inc Company Overview

      • 5.1.1 Adriakaim Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.2 Afferent Technologies Company Overview

      • 5.2.1 Afferent Technologies Pipeline Products & Ongoing Clinical Trials Overview

    • 5.3 Aucta Technologies Inc Company Overview

      • 5.3.1 Aucta Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.4 AURIMOD GmbH Company Overview

      • 5.4.1 AURIMOD GmbH Pipeline Products & Ongoing Clinical Trials Overview

    • 5.5 Boston Scientific Corp Company Overview

      • 5.5.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview

    • 5.6 Cala Health Inc Company Overview

      • 5.6.1 Cala Health Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.7 CerboMed GmbH Company Overview

      • 5.7.1 CerboMed GmbH Pipeline Products & Ongoing Clinical Trials Overview

    • 5.8 Cyberonics Inc Company Overview

      • 5.8.1 Cyberonics Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.9 DuoCure Ltd. Company Overview

      • 5.9.1 DuoCure Ltd. Pipeline Products & Ongoing Clinical Trials Overview

    • 5.10 ElectroCore Inc Company Overview

      • 5.10.1 ElectroCore Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.11 Evren Technologies Inc Company Overview

      • 5.11.1 Evren Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.12 Flint Rehabilitation Company Overview

      • 5.12.1 Flint Rehabilitation Pipeline Products & Ongoing Clinical Trials Overview

    • 5.13 FRD Accel LLC Company Overview

      • 5.13.1 FRD Accel LLC Pipeline Products & Ongoing Clinical Trials Overview

    • 5.14 LivaNova PLC Company Overview

      • 5.14.1 LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview

    • 5.15 Medical University of South Carolina Company Overview

      • 5.15.1 Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview

    • 5.16 MicroTransponder Inc Company Overview

      • 5.16.1 MicroTransponder Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.17 Nemechek Technologies LLC Company Overview

      • 5.17.1 Nemechek Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview

    • 5.18 Nexeon MedSystems Inc Company Overview

      • 5.18.1 Nexeon MedSystems Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.19 Otto Bock HealthCare GmbH Company Overview

      • 5.19.1 Otto Bock HealthCare GmbH Pipeline Products & Ongoing Clinical Trials Overview

    • 5.20 Parasym Ltd Company Overview

      • 5.20.1 Parasym Ltd Pipeline Products & Ongoing Clinical Trials Overview

    • 5.21 Pulsetto UAB Company Overview

      • 5.21.1 Pulsetto UAB Pipeline Products & Ongoing Clinical Trials Overview

    • 5.22 Pulsus Medical LLC (Inactive) Company Overview

      • 5.22.1 Pulsus Medical LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview

    • 5.23 Purdue University Company Overview

      • 5.23.1 Purdue University Pipeline Products & Ongoing Clinical Trials Overview

    • 5.24 ReShape Lifesciences Inc Company Overview

      • 5.24.1 ReShape Lifesciences Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.25 Soterix Medical Inc Company Overview

      • 5.25.1 Soterix Medical Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.26 SUNY Downstate Medical Center Company Overview

      • 5.26.1 SUNY Downstate Medical Center Pipeline Products & Ongoing Clinical Trials Overview

    • 5.27 Synergia Medical SA Company Overview

      • 5.27.1 Synergia Medical SA Pipeline Products & Ongoing Clinical Trials Overview

    • 5.28 Texas Biomedical Device Center Company Overview

      • 5.28.1 Texas Biomedical Device Center Pipeline Products & Ongoing Clinical Trials Overview

    • 5.29 The Feinstein Institute for Medical Research Company Overview

      • 5.29.1 The Feinstein Institute for Medical Research Pipeline Products & Ongoing Clinical Trials Overview

    • 5.30 Trifectas Medical Corp. Company Overview

      • 5.30.1 Trifectas Medical Corp. Pipeline Products & Ongoing Clinical Trials Overview

    • 5.31 University of Alabama Company Overview

      • 5.31.1 University of Alabama Pipeline Products & Ongoing Clinical Trials Overview

    • 5.32 University of Auckland Company Overview

      • 5.32.1 University of Auckland Pipeline Products & Ongoing Clinical Trials Overview

    • 5.33 University of Pittsburgh Company Overview

      • 5.33.1 University of Pittsburgh Pipeline Products & Ongoing Clinical Trials Overview

    • 5.34 University of Wisconsin Madison Company Overview

      • 5.34.1 University of Wisconsin Madison Pipeline Products & Ongoing Clinical Trials Overview

    • 5.35 VA Pittsburgh Healthcare System Company Overview

      • 5.35.1 VA Pittsburgh Healthcare System Pipeline Products & Ongoing Clinical Trials Overview

  • 6 Vagus Nerve Stimulators (VNS)- Recent Developments

  • 7 Appendix

    • 7.1 Methodology

    • 7.2 About GlobalData

    • 7.3 Contact Us

    • 7.4 Disclaimer

Table

Vagus Nerve Stimulators (VNS) – Pipeline Products by Stage of Development 12

Vagus Nerve Stimulators (VNS) – Pipeline Products by Territory 13

Vagus Nerve Stimulators (VNS) – Pipeline Products by Regulatory Path 14

Vagus Nerve Stimulators (VNS) – Pipeline Products by Estimated Approval Date 15

Vagus Nerve Stimulators (VNS) – Ongoing Clinical Trials 16

Vagus Nerve Stimulators (VNS) Companies – Pipeline Products by Stage of Development 17

Vagus Nerve Stimulators (VNS) – Pipeline Products by Stage of Development 19

Adriakaim Inc Pipeline Products & Ongoing Clinical Trials Overview 21

Vagus Nerve Stimulation Device – Product Status 21

Vagus Nerve Stimulation Device – Product Description 21

Afferent Technologies Pipeline Products & Ongoing Clinical Trials Overview 22

WiNerve4 System – Product Status 22

WiNerve4 System – Product Description 22

Aucta Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 23

DECIMA Device – Product Status 23

DECIMA Device – Product Description 23

AURIMOD GmbH Pipeline Products & Ongoing Clinical Trials Overview 24

AuriMod – Product Status 24

AuriMod – Product Description 24

Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 25

AMT System – Product Status 25

AMT System – Product Description 25

Vagus Nerve Stimulation (VNS) System – Product Status 26

Vagus Nerve Stimulation (VNS) System – Product Description 26

Boston Scientific Corp – Ongoing Clinical Trials Overview 27

Vagus Nerve Stimulation (VNS) System – Neural Cardiac Therapy for Heart Failure Study 28

Cala Health Inc Pipeline Products & Ongoing Clinical Trials Overview 29

RAVANS Device – Product Status 29

RAVANS Device – Product Description 29

Wearable Neuromodulation Device – Product Status 30

Wearable Neuromodulation Device – Product Description 30

Cala Health Inc – Ongoing Clinical Trials Overview 31

RAVANS Device – Investigating the Safety and Efficacy of Respiratory-Gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) in Ulcerative Colitis (UC) in Pediatric and Young Adult Populations 32

CerboMed GmbH Pipeline Products & Ongoing Clinical Trials Overview 33

t-VNS – Dementia – Product Status 33

t-VNS – Dementia – Product Description 33

Cyberonics Inc Pipeline Products & Ongoing Clinical Trials Overview 34

Nerve Wrap – Product Status 34

Nerve Wrap – Product Description 34

DuoCure Ltd. Pipeline Products & Ongoing Clinical Trials Overview 35

Intraluminal Implantable Device – Product Status 35

Intraluminal Implantable Device – Product Description 35

ElectroCore Inc Pipeline Products & Ongoing Clinical Trials Overview 36

ElectroCore RMS-1100 Resolution Motility System – Post-Operative Ileus – Product Status 36

ElectroCore RMS-1100 Resolution Motility System – Post-Operative Ileus – Product Description 37

GammaCore – Gastroparesis – Product Status 37

GammaCore – Gastroparesis – Product Description 37

GammaCore – Opioid Use Disorder – Product Status 38

GammaCore – Opioid Use Disorder – Product Description 38

GammaCore – Parkinsonian Gait – Product Status 38

GammaCore – Parkinsonian Gait – Product Description 39

GammaCore – Post-Traumatic Headache – Product Status 39

GammaCore – Post-Traumatic Headache – Product Description 39

GammaCore – Post-Traumatic Stress Disorder – Product Status 40

GammaCore – Post-Traumatic Stress Disorder – Product Description 40

Gammacore – Reactive Airway Disease – Product Status 40

Gammacore – Reactive Airway Disease – Product Description 41

GammaCore – Rheumatoid Arthritis – Product Status 41

GammaCore – Rheumatoid Arthritis – Product Description 41

GammaCore – Sjogren’s Syndrome – Product Status 42

GammaCore – Sjogren’s Syndrome – Product Description 42

GammaCore – Stroke – Product Status 42

GammaCore – Stroke – Product Description 43

GammaCore – Subarachnoid Hemorrhage – Product Status 43

GammaCore – Subarachnoid Hemorrhage – Product Description 43

GammaCore – Traumatic Brain Injury – Product Status 44

GammaCore – Traumatic Brain Injury – Product Description 44

GammaCore – Ulcerative Colitis – Product Status 44

GammaCore – Ulcerative Colitis – Product Description 45

gammaCore Sapphire – Product Status 45

gammaCore Sapphire – Product Description 45

Resolve Stimulator And Proximity Electrode – Product Status 46

Resolve Stimulator And Proximity Electrode – Product Description 46

ElectroCore Inc – Ongoing Clinical Trials Overview 47

gammaCore Sapphire – Non-invasive Vagus Nerve Stimulation in Acute Ischemic Stroke 48

gammaCore Sapphire – Vagus Nerve Stimulation as a Novel Treatment for Systemic Lupus Erythematous: A Double Blinded Randomized Controlled Trail 48

GammaCore – Gastroparesis – Non-invasive Vagal Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients with Gastroparesis and Related Disorders 49

GammaCore – Post-Traumatic Stress Disorder – Transcutaneous Cervical Vagal Nerve Stimulation in Patients with Posttraumatic Stress Disorder (PTSD): A Pilot Study of Effects on PTSD Symptoms and Interleukin-6 Response to Stress 50

GammaCore – Post-Traumatic Stress Disorder – Transcutaneous Vagal Nerve Stimulation in Veterans With Posttraumatic Stress Disorder 50

GammaCore – Subarachnoid Hemorrhage – Safety, Feasibility, and Efficacy of Non-invasive Vagus Nerve Stimulation (nVNS) in the Treatment of Aneurysmal Subarachnoid Hemorrhage: STORM 51

GammaCore – Opioid Use Disorder – Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3 52

GammaCore – Traumatic Brain Injury – Non-Invasive Vagal Nerve Stimulation in Veterans with Mild Traumatic Brain Injury (mTBI) 53

Evren Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 54

Phoenix Earbud Device – Product Status 54

Phoenix Earbud Device – Product Description 54

Flint Rehabilitation Pipeline Products & Ongoing Clinical Trials Overview 55

FitMi VNS System – Product Status 55

FitMi VNS System – Product Description 55

FRD Accel LLC Pipeline Products & Ongoing Clinical Trials Overview 56

BabyStrong TaVNS Bottle Feeding System – Product Status 56

BabyStrong TaVNS Bottle Feeding System – Product Description 56

LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview 57

Aspire NP – Product Status 57

Aspire NP – Product Description 58

Centro Generator – Product Status 58

Centro Generator – Product Description 58

CentroSR Generator – Product Status 59

CentroSR Generator – Product Description 59

EpiTrace – Product Status 59

EpiTrace – Product Description 59

Equilia – Product Status 60

Equilia – Product Description 60

Griffin – Pulse Generator – Product Status 60

Griffin – Pulse Generator – Product Description 61

Intense Neuromodulation System – Heart Failure – Product Status 61

Intense Neuromodulation System – Heart Failure – Product Description 61

Microburst VNS Stimulator – Product Status 61

Microburst VNS Stimulator – Product Description 62

PhoenixRF SR – Product Status 62

PhoenixRF SR – Product Description 62

VITARIA System – Chronic Heart Failure – Product Status 63

VITARIA System – Chronic Heart Failure – Product Description 63

WaveLink – Product Status 63

WaveLink – Product Description 64

LivaNova PLC – Ongoing Clinical Trials Overview 65

VITARIA System – Chronic Heart Failure – Autonomic Regulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure with Reduced Ejection Fraction 66

Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview 67

BabyStrong Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) – Product Status 67

BabyStrong Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) – Product Description 67

Medical University of South Carolina – Ongoing Clinical Trials Overview 68

BabyStrong Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) – BabyStrong taVNS-Paired Bottle Feeding to Improve Oral Feeding 69

MicroTransponder Inc Pipeline Products & Ongoing Clinical Trials Overview 70

SAINT System – Anxiety Disorders – Product Status 70

SAINT System – Anxiety Disorders – Product Description 70

SAINT System – Tinnitus – Product Status 71

SAINT System – Tinnitus – Product Description 71

Serenity System – Product Status 71

Serenity System – Product Description 72

Nemechek Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview 73

Vitality Smartcable – COVID-19 – Product Status 73

Vitality Smartcable – COVID-19 – Product Description 73

Nexeon MedSystems Inc Pipeline Products & Ongoing Clinical Trials Overview 74

Auricular Vagus Nerve Stimulator – Asthma – Product Status 74

Auricular Vagus Nerve Stimulator – Asthma – Product Description 74

aVNS Device – Product Status 75

aVNS Device – Product Description 75

Vagus Nerve Stimulator – Asthma – Product Status 75

Vagus Nerve Stimulator – Asthma – Product Description 76

Otto Bock HealthCare GmbH Pipeline Products & Ongoing Clinical Trials Overview 77

Neuromodulation Device – Epilepsy – Product Status 77

Neuromodulation Device – Epilepsy – Product Description 77

Neuromodulation Device – Sleep Apnea – Product Status 78

Neuromodulation Device – Sleep Apnea – Product Description 78

Parasym Ltd Pipeline Products & Ongoing Clinical Trials Overview 79

Parasym Device – Product Status 79

Parasym Device – Product Description 79

Parasym Ltd – Ongoing Clinical Trials Overview 80

Parasym Device – Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A) 81

Parasym Device – Multimodal Investigation of Post COVID-19 in Females: A Pilot Study 81

Parasym Device – Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis 81

Parasym Device – Non-invasive Vagal Stimulation for Frequent Premature Ventricular Complexes (NoVa-PVC) 82

Parasym Device – The Effect of Different Low-level Tragus Stimulation Parameters on Autonomic Nervous System Function 82

Parasym Device – Transcutaneous Vagal Nerve Stimulation to Prevent Tachyarrhythmias in Patients Early Following Myocardial Infarction: A Randomized Clinical Trial 82

Pulsetto UAB Pipeline Products & Ongoing Clinical Trials Overview 83

Vagus Nerve Stimulator – Product Status 83

Vagus Nerve Stimulator – Product Description 83

Pulsus Medical LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 84

VNS Device – Product Status 84

VNS Device – Product Description 84

Purdue University Pipeline Products & Ongoing Clinical Trials Overview 85

Bionode Device – Product Status 85

Bionode Device – Product Description 85

ReShape Lifesciences Inc Pipeline Products & Ongoing Clinical Trials Overview 86

Diabetes Bloc-Stim Neuromodulation Device – Product Status 86

Diabetes Bloc-Stim Neuromodulation Device – Product Description 86

Diabetes Bloc-Stim Neuromodulation Device – Hypoglycemia – Product Status 87

Diabetes Bloc-Stim Neuromodulation Device – Hypoglycemia – Product Description 87

Soterix Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 88

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) Device – Product Status 88

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) Device – Product Description 88

Soterix Medical Inc – Ongoing Clinical Trials Overview 89

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) Device – Clinical Trial Evaluating the Efficacy of Home-based Auricular Vagus Nerve Stimulation (taVNS) in Post-COVID-19 Subjects 90

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) Device – Extending taVNS Paired With Infant CIMT Into a Home-Based Setting: Technology Development Requisite for a Randomized Trial 90

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) Device – Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for Persistent Symptoms from Lyme Disease: A Feasibility, Tolerability, and Safety Study 90

SUNY Downstate Medical Center Pipeline Products & Ongoing Clinical Trials Overview 91

Vagus Nerve Stimulator – Ventricular Arrhythmia – Product Status 91

Vagus Nerve Stimulator – Ventricular Arrhythmia – Product Description 91

Synergia Medical SA Pipeline Products & Ongoing Clinical Trials Overview 92

NAO·VNS – Chronic Pain – Product Status 92

NAO·VNS – Chronic Pain – Product Description 92

NAO·VNS – Depression – Product Status 93

NAO·VNS – Depression – Product Description 93

NAO·VNS – Epilepsy – Product Status 93

NAO·VNS – Epilepsy – Product Description 94

NAO·VNS – Parkinson’s Disease – Product Status 94

NAO·VNS – Parkinson’s Disease – Product Description 94

NAO·VNS – Sleep Apnoea – Product Status 95

NAO·VNS – Sleep Apnoea – Product Description 95

Texas Biomedical Device Center Pipeline Products & Ongoing Clinical Trials Overview 96

ReStore Wireless Vagus Nerve Stimulator – Product Status 96

ReStore Wireless Vagus Nerve Stimulator – Product Description 96

Texas Biomedical Device Center – Ongoing Clinical Trials Overview 97

ReStore Wireless Vagus Nerve Stimulator – Wireless Nerve Stimulation Device to Enhance Recovery after Stroke 98

The Feinstein Institute for Medical Research Pipeline Products & Ongoing Clinical Trials Overview 99

Bioelectronic Medicine Device – Heart Failure – Product Status 99

Bioelectronic Medicine Device – Heart Failure – Product Description 99

Bioelectronic Medicine Device – Lupus – Product Status 100

Bioelectronic Medicine Device – Lupus – Product Description 100

Bioelectronic Medicine Device – Obesity – Product Status 100

Bioelectronic Medicine Device – Obesity – Product Description 101

Bioelectronic Medicine Device – Pulmonary Hypertension – Product Status 101

Bioelectronic Medicine Device – Pulmonary Hypertension – Product Description 101

Neurochip – Product Status 102

Neurochip – Product Description 102

Trifectas Medical Corp. Pipeline Products & Ongoing Clinical Trials Overview 103

Neurostimulation Device – Stroke Recovery – Product Status 103

Neurostimulation Device – Stroke Recovery – Product Description 103

University of Alabama Pipeline Products & Ongoing Clinical Trials Overview 104

VNS Device – Depression – Product Status 104

VNS Device – Depression – Product Description 104

University of Auckland Pipeline Products & Ongoing Clinical Trials Overview 105

Electroceutical Device – Product Status 105

Electroceutical Device – Product Description 105

University of Pittsburgh Pipeline Products & Ongoing Clinical Trials Overview 106

Closed-Loop Neuroelectric Device – Product Status 106

Closed-Loop Neuroelectric Device – Product Description 106

University of Wisconsin Madison Pipeline Products & Ongoing Clinical Trials Overview 107

Implantable Weight-Loss Device – Product Status 107

Implantable Weight-Loss Device – Product Description 107

VA Pittsburgh Healthcare System Pipeline Products & Ongoing Clinical Trials Overview 108

Auricular Vagus Nerve Stimulation Device – Product Status 108

Auricular Vagus Nerve Stimulation Device – Product Description 108

Glossary 118

Figures

Vagus Nerve Stimulators (VNS) – Pipeline Products by Stage of Development 11

Vagus Nerve Stimulators (VNS) – Pipeline Products by Territory 12

Vagus Nerve Stimulators (VNS) – Pipeline Products by Regulatory Path 13

Vagus Nerve Stimulators (VNS) – Pipeline Products by Estimated Approval Date 14

Vagus Nerve Stimulators (VNS) – Ongoing Clinical Trials 15

Frequently asked questions

Vagus Nerve Stimulators (VNS) Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies standard reports
Currency USD
$4,000

Can be used by individual purchaser only

Most Popular
$8,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$12,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Vagus Nerve Stimulators (VNS) Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Vagus Nerve Stimulators (VNS) reports
Medical Devices
New
PTA Peripheral DCB Catheters Pipeline by Development Stages, Segments, Region…
$4,000 | March 2024
Medical Devices
New
Immunochemistry Analyzers Market Size by Segments, Share, Regulatory, Reimbursement, Installed…
$7,500 | March 2024
Medical Devices
New
PCR Systems Market Size by Segments, Share, Regulatory, Reimbursement, Installed…
$7,500 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Vagus Nerve Stimulators (VNS) Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies in real time.

  • Access a live Vagus Nerve Stimulators (VNS) Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more